|
1) 林田美江, 藤本圭作, 久保惠嗣, 他. 肺リンパ脈管筋腫症に関する全国疫学調査, 追跡調査および第2回目全国横断調査. 厚生労働省難治性疾患呼吸不全に関する調査研究. 平成19年度総括・分担研究報告書. 2008; 37-41
|
|
|
|
|
2) Sugimoto R, Nakao A, Yamane M, et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant. 2008; 27: 921-4
|
|
|
|
|
3) Ohara T, Oto T, Miyoshi K, et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg. 2008; 86: e7-8
|
|
|
|
|
|
4) Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 140-51
|
|
|
|
|
|
5) McCormack FX, Inoue Y, MossJ, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364: 1595-606
|
|
|
|
|
|
6) 瀬山邦明, 佐藤輝彦, 郡司陽子, 他. 乳び胸腹水合併LAM症例における低用量GnRH療法の効果. 厚生労働省特定疾患呼吸不全に関する調査研究. 平成18年度研究報告書. 2007; 116-20
|
|
|
|
|
|
7) 瀬山邦明, 飛野和則, 郡司陽子, 他. GnRH療法の呼吸機能および血清VEGF-D値に対する影響. 厚生労働省特定疾患呼吸不全に関する調査研究. 平成19年度研究報告書. 2008; 94-6
|
|
|
|
|
|
8) Taveira-DaSilva AM, Stylinou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or with out progesterone. Chest. 2004; 126: 1867-74
|
|
|
|
|
|
9) 林田美江, 藤本圭作, 久保惠嗣, 他. リンパ脈管筋腫症 lymphangioleiomyomatosis (LAM) の治療と管理の手引き. 日呼吸会誌. 2008; 46: 428-31
|
|
|
|
|
10) 井上恵美, 瀬山邦明, 佐藤輝彦, 他. リンパ脈管筋腫症(LAM)における吸入気管支拡張療法の有用性について. 厚生労働省難治性疾患呼吸不全に関する調査研究. 平成16年度研究報告書. 2005; 113-6
|
|
|
|
|
|
11) Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35: 14-26
|
|
|
|
|
|
12) Kurihara M, Kataoka H, Ishikawa A, et al. Latest treatments for spontaneous pneumothorax. Gen Thorac Cardiovasc Surg. 2010; 58: 113-9
|
|
|
|
|
|
13) Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000; 97: 6085-90
|
|
|
|
|
|
14) Sato T, Seyama K, Fujii H, et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet. 2002; 47: 20-8
|
|
|
|
|
|
15) Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor independent pathway that regulates the cytoskeleton. Curr Biol. 2004; 14: 1296-302
|
|
|
|
|
|
16) Finlay GA, York B, Karas RH, et al. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-β and ERK-1/2. J Biol Chem. 2004; 279: 23114-22
|
|
|
|
|
|
17) York B, Lou D, Panettieri R, et al. Cross-talk between tuberin, calmodulin, and estrogen signaling pathways. FASEB J. 2005; 19: 1202-4
|
|
|
|
|
|
18) Taveira-DaSilva AM, Hathaway O, Stylianou M, et al. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011; 154: 797-805
|
|
|
|
|
|
19) Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: A phase 2 trial. Clin Cancer Res. 2011; 17: 4071-81
|
|
|
|
|
|
20) Chen F, Omasa M, Kondo N, et al. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplant. Ann Thorac Surg. 2009; 87: e6-7
|
|
|
|
|
|
21) El-Hashemite N, Kwiatkowski DJ. Interferon-gamma-Jak-stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target. Am J Respir Cell Mol Biol. 2005; 33: 227-30
|
|
|
|
|
|
22) Terasaki Y, Yahiro K, Pacheco-Rodriguez G, et al. Effects of prolactin on TSC2-Null eker rat cells and in pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2010; 182: 531-9
|
|
|
|
|
|
23) Valencia JC, Matsui K, Bondy C, et al. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. J Investig Med. 2001; 49: 421-33
|
|
|
|
|
|
24) Ikeda Y, Taveira-DaSilva AM, Pacheco-Rodriguez G, et al. Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2. Am J Physiol Lung Cell Mol Physiol. 2011; 300: L64-72
|
|
|
|
|
|
25) El-Hashemite N, Zhang H, Walker V, et al. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription singaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res. 2004; 64: 3436-43
|
|
|
|
|
|
26) Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 2005; 29: 1356-66
|
|
|
|
|
|
27) Cai X, Pacheco-Rodriguez G, Fan QY, et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2010; 182: 1410-18
|
|
|
|
|
|
28) Pacheco-Rodriguez G, Kumaki F, Steaqall WK, et al. Chemokine-enhanced chemotaxis of lymph-angioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol. 2009; 182: 1270-77
|
|
|
|
|
|
29) Secko D. For mTOR, clarification and confusion. The Scientist. 2006; 20: 59
|
|
|
|
|